Status:
COMPLETED
PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)
Lead Sponsor:
UNC Lineberger Comprehensive Cancer Center
Conditions:
Neurofibromatosis-1
Optic Glioma
Eligibility:
All Genders
6+ years
Brief Summary
This prospective pilot study is designed to provide preliminary data on the use of Fluorodeoxyglucose Positron Emission Tomography-Magnetic Resonance Imaging (FDG-PET-MRI) in patients with neurofibrom...
Eligibility Criteria
Inclusion
- Diagnosed with neurofibromatosis-1 with either optic glioma, due for imaging scan, or plexiform neurofibroma, due for imaging secondary to clinical signs or symptoms of progressive disease
- ≥ 6 years of age
- English-speaking
- If female of child-bearing potential, negative urine pregnancy test performed within 7 days prior to each FDG-PET-MRI
- Study-specific informed consent or assent obtained and signed
Exclusion
- Unable to undergo FDG-PET-MRI without sedation
- Currently undergoing chemotherapy for progressing optic glioma
- Pregnant or lactating female
- Poorly controlled diabetes mellitus
- Presence of pacemaker, intracranial aneurysm clip, cochlear implant, metal halo device, epicardial pacemaker leads, or any other device that makes MRI unsafe
- Serum creatinine \> 1.8 mg/dL OR GFR \< 30 mL/min
- Unable to lie flat for \> 1 hour
- Body Mass Index (BMI) \> 35
Key Trial Info
Start Date :
January 16 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 5 2019
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01800032
Start Date
January 16 2013
End Date
December 5 2019
Last Update
May 12 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of North Carolina-Chapel Hill
Chapel Hill, North Carolina, United States, 27599